Capital International Investors
ANAB icon

Capital International Investors’s AnaptysBio ANAB Stock Holding History

Capital International Investors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-161,700
Closed -$5.66M – 396
2019
Q3 		$5.66M Hold
161,700
– – ﹤0.01% 374
2019
Q2 		$9.12M Hold
161,700
– – ﹤0.01% 363
2019
Q1 		$11.8M Hold
161,700
– – 0.01% 348
2018
Q4 		$10.3M Buy
161,700
+16,700
+12% +$1.24M 0.01% 342
2018
Q3 		$14.5M Buy
+145,000
New +$12M 0.01% 336

Other funds holding ANAB

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital International Investors's ANAB Position: Q4 2019 in Review

Capital International Investors sold out of AnaptysBio (ANAB) in Q4 2019, closing a stake of 161,700 shares — an estimated $5.66M sold.

Capital International Investors first reported a position in ANAB in Q3 2018 and held it in 5 quarters. The position peaked at $14.5M in Q3 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

  • Capital International Investors reported no remaining AnaptysBio position as of Q4 2019 after selling out during the quarter.
  • Capital International Investors sold 161,700 AnaptysBio shares in Q4 2019, an estimated $5.66M.
  • Capital International Investors first reported a position in AnaptysBio in Q3 2018 and held it in 5 quarters.
  • Capital International Investors's AnaptysBio position peaked at $14.5M in Q3 2018.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on Capital International Investors's 13F filing for Q4 2019, filed 18 Feb 2020.